Fig. 1: Clinical and laboratory characteristics of an infant with severe COVID-19. | Communications Medicine

Fig. 1: Clinical and laboratory characteristics of an infant with severe COVID-19.

From: A case report describing the immune response of an infant with congenital heart disease and severe COVID-19

Fig. 1

A Clinical timeline showing immuno-modulatory therapies in relation to clinical course. B Plain chest film performed on admission illustrating bilateral interstitial infiltrates with left lower lobe collapse and consolidation. C Virologic findings illustrating SARS-CoV-2 Cycle threshold Ct values in naso-/oropharyngeal and urine specimens that reduce in association with clinical improvement. D Serum IgG, IgM, and IgA to S1 using in-house ELISA modified from Mount Sinai Laboratories, USA; and microneutralisation assay demonstrating a rapid rise in neutralising antibody titres. E Elevated ferritin and LDH with initial hyper-inflammatory picture and rapid reduction in ferritin coinciding with clinical improvement. F Persistent lymphopaenia; initial high IL-6 with reduction after administration of tocilizumab. IVIG intravenous immunoglobulin, LDH lactate dehydrogenase, NPA nasopharyngeal aspirate, EU ELISA units, Ct cycle threshold.

Back to article page